Search Results for "establish"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for establish. Results 561 to 570 of 656 total matches.

Comparison Table: Some Drugs for Weight Management (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025  (Issue 1734)
relationship has not been established ▶ Increases oxalate absorption and may increase the risk of developing ...
View the Comparison Table: Some Drugs for Weight Management
Med Lett Drugs Ther. 2025 Aug 4;67(1734):e127-30   doi:10.58347/tml.2025.1734b |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
clinician; the equianalgesic dose of methadone is not well established in opioid-tolerant patients ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction

Drugs for Alcohol Use Disorder

   
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021  (Issue 1639)
-approved for treatment of the disorder.2 TREATMENT GOALS — Establishing specific goals before starting ...
Consumption of alcohol has increased during the COVID-19 pandemic. The Diagnostic and Statistical Manual for Mental Disorders, 5th edition (DSM-5) defines alcohol use disorder (AUD; previously called alcohol dependence) as meeting ≥2 of the 11 criteria listed in Table 1 in the past year. The lifetime prevalence of AUD in the US population has been estimated to be about 30%. Despite this high prevalence and the associated morbidity, mortality, and costs, only 3 drugs are FDA-approved for treatment of the disorder.
Med Lett Drugs Ther. 2021 Dec 13;63(1639):193-8 |  Show IntroductionHide Introduction

Drugs for Menopausal Symptoms

   
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024  (Issue 1697)
. Whether ospemifene is safe for use in women with or at risk for breast cancer remains to be established ...
The primary symptoms of menopause are genitourinary and vasomotor. The genitourinary syndrome of menopause (GSM) includes symptoms such as burning, irritation, dryness, dyspareunia, dysuria, and recurrent urinary tract infection. Vasomotor symptoms (VMS; hot flashes, night sweats) often disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8   doi:10.58347/tml.2024.1697a |  Show IntroductionHide Introduction

Three New Drugs for Hyperlipidemia

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003  (Issue 1151)
safety of using them concurrently has not been established. Cholestyramine and presumably colestipol ...
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin (Mevacor, and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Med Lett Drugs Ther. 2003 Mar 3;45(1151):17-9 |  Show IntroductionHide Introduction

Drug Interactions with Grapefruit Juice

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2004  (Issue 1173)
; clinical importance not established Itraconazole (Sporanox) Possible decreased effect Avoid concurrent use ...
The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).
Med Lett Drugs Ther. 2004 Jan 5;46(1173):2-4 |  Show IntroductionHide Introduction

Palladone for Chronic Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005  (Issue 1204)
was established by an unpublished 4week, randomized, double-blind trial in 221 patients with chronic moderate ...
A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride (Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with persistent moderate to severe pain. Hydromorphone HCl, a semisynthetic congener of morphine and active metabolite of hydrocodone that has been used since the 1920s, is also available in immediate-release oral, injectable and suppository forms (Dilaudid, and others).
Med Lett Drugs Ther. 2005 Mar 14;47(1204):21-3 |  Show IntroductionHide Introduction

Sildenafil (Revatio) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005  (Issue 1215)
with the other therapies for this condition remains to be established. 1. Sildenafil for pulmonary hypertension. Med Lett ...
The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio.
Med Lett Drugs Ther. 2005 Aug 15;47(1215):65-7 |  Show IntroductionHide Introduction

Adacel and Boostrix: Tdap Vaccines for Adolescents and Adults

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006  (Issue 1226)
the prevalence of pertussis and prevent infection of unvaccinated children remains to be established. 1 ...
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine...
Med Lett Drugs Ther. 2006 Jan 16;48(1226):5-6 |  Show IntroductionHide Introduction

Abatacept (Orencia) for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006  (Issue 1229)
established rheumatoid arthritis: results from the AIM trial [presentation 1494]. Annual meeting ...
Atacept (Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Med Lett Drugs Ther. 2006 Feb 27;48(1229):17-8 |  Show IntroductionHide Introduction